查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1924720

口服多发性硬化症治疗药物市场（依分子、药物类别、适应症、治疗阶段、剂型及通路）——2026-2032年全球预测

Oral Medications for Multiple Sclerosis Market by Molecule, Drug Class, Indication, Line Of Therapy, Dosage Form, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，多发性硬化症口服药物市场价值将达到 63.7 亿美元，到 2026 年将成长至 67.6 亿美元，到 2032 年将达到 104.4 亿美元，年复合成长率为 7.31%。

关键市场统计数据
基准年 2025 63.7亿美元
预计年份：2026年 67.6亿美元
预测年份 2032 104.4亿美元
复合年增长率 (%) 7.31%

针对不断发展的口服多发性硬化症治疗生态系统，制定一项策略性方法，将临床差异化与商业性和市场准入优先事项结合。

由于治疗方案组合、监管环境和治疗路径的不断演变，口服多发性硬化症治疗领域正经历重大重组。本概要旨在为高阶主管、临床开发负责人、支付方负责人和商业团队提供结构化的指导，帮助他们简洁全面地了解当前趋势和即将到来的转折点。重点在于口服缓解疾病治疗药物（DMARDs），这些药物具有不同的作用机制，会对处方模式、病患依从性以及医疗照护目录谈判产生影响。

基于机制的差异化、加强监管以及循证商业模式将如何重塑口服多发性硬化症治疗药物的研发路径和市场动态

口服多发性硬化症治疗领域正经历一场变革，这场变革正在重新定义治疗方法的研发、处方以及在医疗保健系统中的整合方式。基于机制的差异化是商业策略的核心。富马酸酯类、鞘氨醇-1-磷酸受体调变器和二氢乳清酸去氢酶抑制剂各自具有不同的疗效和安全性权衡，临床医生可以利用这些权衡，根据疾病活动度、合併症情况和患者意愿来制定个人化治疗方案。这种分子层次和类别层面的多样性凸显了头对头资料、长期安全性监测和真实世界证据对于指导治疗顺序决策的重要性。

2025年前对口服多发性硬化症疗法的影响：在美国关税变化和全球采购压力下管理供应链韧性和商业性连续性

2025年美国即将生效的新关税政策和贸易趋势将进一步增加口服多发性硬化症治疗药物生产商和相关人员的复杂性。关税调整将影响原料药、辅料、包装材料和成品的到岸成本，而这些都依赖全球生产和采购网络。因此，企业将更加重视加强供应链韧性、实现供应商多元化以及优化服务交付成本，以在确保可预测的供应的同时保护利润率。

将分子特征、治疗领域、适应症和分销管道趋势联繫起来的细分市场洞察，为证据、准入和商业化策略提供资讯。

一项涵盖分子特征、治疗领域、临床适应症、治疗顺序、剂型和分销管道的详细細項分析揭示了关键机会和限制因素。以分子为中心观点，可以区分出富马酸二甲酯、富马酸二甲酯、Fingolimod、富马酸单甲酯、ozanimod、Ponesimod、Siponimod和特立氟胺等药物。每种药物都具有独特的特征，这些特征会影响耐受性、监测需求和患者偏好。这些个人化的分子特征会影响处方医师的选择，也是疗效比较评估和药物目录协商的核心基础。

美洲、欧洲、中东和非洲以及亚太地区的市场准入和支付方趋势将影响口服多发性硬化症药物的市场上市顺序和长期应用。

区域趋势对于理解临床实践、监管预期和支付方行为如何相互交织，共同影响口服多发性硬化症药物的可及性至关重要。在美洲，人口结构的变化、支付方影响力的集中以及已建立的专科药房网络，使得处方集谈判和基于疗效的安排成为关键考虑因素。在该地区运营的製药企业必须设计完善的市场进入材料，投资收集真实世界证据，并製定有针对性的患者援助计划，以减少处方和配药过程中的摩擦。

製造商、生物技术创新者和通路伙伴如何协调生命週期、商业和营运策略，以确保口服多发性硬化症治疗药物的可近性和规模化应用？

在口服多发性硬化症领域，各公司采取的策略体现了多元化的方法，涵盖分子创新、生命週期管理、商业性执行和生态系统伙伴关係。创新先行者专注于透过扩展安全性资料库、优化适应症和产生比较疗效证据来实现差异化。此外，他们还投资于患者支援基础设施、数位依从性解决方案和集中式报销团队，以应对复杂的支付方要求并保持处方医生的信心。

产业领导者在口服多发性硬化症疗法商业化过程中整合证据、供应链弹性、病患支持和适应性合约的实用策略重点

为了在口腔多发性硬化症领域创造永续价值，产业领导者应采取多管齐下的策略，整合临床差异化、实证医学证据和商业性弹性。首先，应优先制定严谨的循证方案，包括尽可能开展头对头试验、建立可靠的真实世界证据项目以及建立长期安全性註册登记系统，以直接解决支付方的担忧和临床医生的决策标准。这些实证基础的设计应同时支持国家卫生技术评估和区域支付方对话。

严谨的混合方法调查方法，融合了临床文献回顾、相关人员访谈和三角验证证据，检验有关口腔多发性硬化症的研究结果。

本分析的调查方法融合了第一手和第二手研究，并采用严谨的三角验证法，以确保分析的稳健性和实用性。第二手研究包括对同侪审查的临床文献、监管申报文件、处方指南和公共政策声明进行全面审查，以确定口服多发性硬化症药物的临床和监管背景。为了完善这项基础，本研究也整合了治疗路径文献和医疗服务报告，以绘製通路和获取管道图。

将临床差异化、营运韧性和客製化市场进入相结合，为口腔多发性硬化症相关人员提供可操作的结论，实现高水准的整合。

总之，口服多发性硬化症药物的市场环境日益复杂，同时也为建立策略优势指明了方向。富马酸盐、鞘氨醇受体调变器和二氢乳清酸去氢酶抑制剂等药物的分子多样性丰富了治疗选择，但也凸显了比较证据和差异化价值提案的必要性。 2025年的关税和供应链考量为市场营运增添了新的维度，迫使製造商比以往任何时候都更加紧密地整合成本、韧性和市场准入策略。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 分子层面的口服多发性硬化症治疗市场

  • 富马酸二甲酯
  • 富马酸二甲酯
  • Fingolimod
  • 富马酸单甲酯
  • ozanimod
  • Ponesimod
  • Siponimod
  • Teriflunomide

9. 依药物类别分類的口服多发性硬化症药物市场

  • 二氢乳清酸去氢酶抑制剂
  • 富马酸盐
    • 富马酸二甲酯
    • 富马酸二甲酯
    • 富马酸单甲酯
  • 鞘氨醇-1-磷酸受体调变器
    • Fingolimod
    • ozanimod
    • Ponesimod
    • Siponimod

第十章 依适应症分類的口服多发性硬化症治疗市场

  • 临床孤立症候群
  • 復发型多发性硬化症
  • 次发渐进型多发性硬化症（活动期）

第十一章 依治疗阶段分類的口服多发性硬化症药物市场

  • 主要治疗
  • 后续治疗
  • 二级治疗

第十二章 依剂型分類的口服多发性硬化症治疗市场

  • 胶囊
  • 药片

13. 多发性硬化症口服治疗药物市场（依分销管道划分）

  • 医院药房
  • 零售药房
  • 专科药房

14. 各地区口服多发性硬化症药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 多发性硬化症口服治疗药物市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各国口服多发性硬化症药物市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

17. 美国用于治疗多发性硬化症的口服药物市场

第十八章：中国多发性硬化症口服药物市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Acorda Therapeutics, Inc.
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Clene Nanomedicine, Inc.
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Immensa Biotherapeutics, Inc.
  • Immunic, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Merck KGaA
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Oryzon Genomics, SA
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-7A380DA7C450

The Oral Medications for Multiple Sclerosis Market was valued at USD 6.37 billion in 2025 and is projected to grow to USD 6.76 billion in 2026, with a CAGR of 7.31%, reaching USD 10.44 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.37 billion
Estimated Year [2026] USD 6.76 billion
Forecast Year [2032] USD 10.44 billion
CAGR (%) 7.31%

A strategic orientation to the evolving oral therapy ecosystem for multiple sclerosis that aligns clinical differentiation with commercial and access priorities

The oral multiple sclerosis landscape is undergoing a significant recalibration driven by evolving therapeutic portfolios, regulatory trajectories, and shifting care pathways. This summary provides a structured orientation for senior executives, clinical development leads, payer strategists, and commercial teams who require a concise yet comprehensive synthesis of current dynamics and near-term inflection points. The focus is on oral disease-modifying therapies, where molecules with diverse mechanisms of action are influencing prescribing patterns, adherence outcomes, and formulary negotiations.

In recent years, the proliferation of oral options has altered the balance between efficacy, safety, convenience, and cost considerations, prompting clinicians and health systems to rethink traditional routing through infusion or injectable channels. As a result, stakeholders must understand how molecular differentiation, class-specific safety profiles, and patient-centric attributes such as dosing regimens and tolerability are shaping first-line adoption and subsequent sequencing strategies. This introduction sets the scene for deeper analysis of transformative shifts, tariff-driven cost pressures, segmentation-level implications, regional patterns, company strategies, and recommended actions that follow in the full executive summary.

By synthesizing clinical, regulatory, commercial, and distribution perspectives, this document underscores the multifaceted pressures and opportunities that oral multiple sclerosis therapies present. It aims to equip decision-makers with the contextual intelligence needed to prioritize investments, refine value propositions, and align cross-functional plans for optimized patient access and sustained competitive advantage.

How mechanism-led differentiation, regulatory vigilance, and evidence-driven commercial models are reshaping oral multiple sclerosis treatment pathways and market dynamics

The oral multiple sclerosis treatment environment is in the midst of transformative shifts that are reframing how therapies are developed, prescribed, and integrated into health systems. Mechanism-driven differentiation is now a central commercial lever: fumarates, sphingosine 1 phosphate receptor modulators, and dihydroorotate dehydrogenase inhibitors each convey distinct efficacy and safety trade-offs that clinicians use to tailor therapy to disease activity, comorbidity profiles, and patient preferences. This molecular and class diversity has increased the importance of head-to-head data, long-term safety surveillance, and real-world evidence to guide sequencing decisions.

Concurrently, regulatory pathways and labeling updates have emphasized safety monitoring and post-authorization commitments, prompting manufacturers to invest more heavily in pharmacovigilance and patient support services. These developments are catalyzing partnerships between commercial, medical affairs, and market access teams to align evidence-generation plans with reimbursement needs. Moreover, advances in patient-centric care models, digital adherence tools, and decentralized dispensing are enhancing uptake of oral therapies by reducing barriers associated with clinic visits and infusion center capacity constraints.

On the payer and provider side, value-based contracting and outcomes-based agreements are gaining traction as mechanisms to manage uncertainty around long-term effects and to align price with observed clinical benefit. Pharmaceutical manufacturers are responding with tailored pricing strategies and targeted education for prescribers and payers that highlight differentiating attributes such as tolerability, switching pathways, and monitoring requirements. Taken together, these shifts are creating a more dynamic marketplace where clinical nuance, evidence strategy, and commercial agile capabilities determine which therapies capture durable adoption.

Managing supply chain resilience and commercial continuity amid United States tariff fluctuations and global sourcing pressures affecting oral multiple sclerosis therapies in 2025

Emerging tariff policies and trade dynamics in the United States during 2025 introduce an additional layer of complexity for manufacturers and supply chain stakeholders in the oral multiple sclerosis arena. Tariff adjustments affect landed costs of active pharmaceutical ingredients, excipients, packaging materials, and finished products that rely on global manufacturing and sourcing networks. The result is an increased emphasis on supply chain resilience, supplier diversification, and cost-to-serve optimization to maintain predictable access while protecting margins.

Manufacturers with vertically integrated supply chains or local production capabilities are positioned to mitigate some tariff-driven cost exposure, while those dependent on cross-border sourcing must evaluate hedging strategies, renegotiation of supplier terms, and potential repricing measures. These pressures are likely to accelerate near-shoring and the reallocation of manufacturing capacity to jurisdictions with favorable trade regimes and stable logistics infrastructure. In parallel, commercial teams will need to engage payers proactively to contextualize any price adjustments and to explore risk-sharing constructs that protect patient access.

From a clinical operations standpoint, tariff-induced cost volatility underscores the importance of maintaining unfettered access to critical therapies through robust inventory planning and alternative distribution channels. Specialty pharmacies and hospital procurement organizations will play pivotal roles in buffering short-term supply disruptions, while manufacturers will need transparent communication protocols to preserve trust with providers and patients. Ultimately, managing the cumulative impact of tariffs in 2025 requires integrated cross-functional planning that balances commercial strategy, regulatory compliance, and operational agility to safeguard continuity of care.

Segment-level intelligence connecting molecule attributes, therapeutic classes, indications, and channel dynamics to inform evidence, access, and commercialization tactics

A granular segmentation lens reveals critical opportunities and constraints across molecule-level attributes, therapeutic classes, clinical indications, treatment sequencing, dosage forms, and distribution channels. The molecule-focused perspective distinguishes agents such as Dimethyl Fumarate, Diroximel Fumarate, Fingolimod, Monomethyl Fumarate, Ozanimod, Ponesimod, Siponimod, and Teriflunomide, each presenting unique profiles that influence tolerability, monitoring needs, and patient preference. These individual molecule characteristics inform prescriber choice and are core inputs for comparative effectiveness assessments and formulary negotiations.

At the drug-class level, the market divides into dihydroorotate dehydrogenase inhibitors, fumarates, and sphingosine 1 phosphate receptor modulators. The dihydroorotate dehydrogenase inhibitor class is exemplified by Teriflunomide, a once-daily oral agent with a distinct safety monitoring regimen. The fumarates, which include Dimethyl Fumarate, Diroximel Fumarate, and Monomethyl Fumarate, are often evaluated for their shared efficacy signals as well as differences in gastrointestinal tolerability and tolerability management strategies. The sphingosine 1 phosphate receptor modulators-Fingolimod, Ozanimod, Ponesimod, and Siponimod-are differentiated by selectivity, cardiac monitoring requirements, and pharmacokinetic profiles that influence initiation protocols and switching pathways.

Clinical indication segmentation spans clinically isolated syndrome, relapsing remitting multiple sclerosis, and secondary progressive multiple sclerosis active. These indication strata drive therapeutic intent, with early disease stages placing a premium on relapse reduction and long-term disability prevention, while active secondary progressive disease elevates the importance of neuroprotective effect and disability progression endpoints. Line-of-therapy distinctions between first line, second line, and later line use affect payer positioning and patient access pathways. Dosage form considerations-capsule versus tablet-further influence adherence and manufacturing decisions, while distribution channel segmentation across hospital pharmacy, retail pharmacy, and specialty pharmacy impacts logistics, patient support, and reimbursement workflows. Integrating these segmentation layers yields actionable insights for positioning, evidence generation, and channel-centric commercialization.

Regional access and payer dynamics across Americas, Europe Middle East & Africa, and Asia-Pacific that determine launch sequencing and long-term uptake for oral therapies

Regional dynamics are essential to understanding how clinical practice, regulatory expectations, and payer behavior converge to shape access for oral multiple sclerosis therapies. In the Americas, demographic shifts, concentrated payer influence, and established specialty pharmacy networks create an environment where formulary negotiations and outcomes-based arrangements are prominent considerations. Manufacturers operating in this region must design robust market access dossiers, invest in real-world evidence capture, and deploy targeted patient support programs to reduce friction at the point of prescribing and dispensing.

The Europe, Middle East & Africa region presents a heterogeneous regulatory and payer landscape where centralized and national-level decision-making can produce variable timelines for reimbursement and differing requirements for cost-effectiveness evidence. Health technology assessment bodies and national formularies often emphasize long-term comparative effectiveness and budget impact, necessitating tailored evidence packages and pricing approaches that reflect country-specific constraints and value frameworks. In many EMEA markets, hospital tendering and centralized procurement further influence uptake trajectories, prompting manufacturers to calibrate contracting and supply strategies accordingly.

Across the Asia-Pacific region, rapid adoption of oral therapies is shaped by diverse healthcare infrastructures, variable reimbursement capacity, and increasing investment in specialty care. Local manufacturing capabilities, government-driven price controls, and evolving regulatory pathways shape launch sequencing decisions. Success in this region frequently depends on localized clinical engagement, adaptive pricing models, and partnerships with regional distributors and specialty pharmacies to ensure sustainable access and scale.

How manufacturers, biotech innovators, and channel partners are aligning lifecycle, commercial, and operational strategies to secure access and scale for oral multiple sclerosis agents

Company-level strategies in the oral multiple sclerosis space reflect a spectrum of approaches spanning molecule innovation, lifecycle management, commercial execution, and ecosystem partnerships. Innovative originators have concentrated efforts on differentiating through expanded safety databases, label optimization, and the generation of comparative effectiveness evidence. These activities are complemented by investments in patient support infrastructure, digital adherence solutions, and centralized reimbursement teams to navigate complex payer requirements and to preserve prescriber confidence.

Emerging biotechnology firms and specialty players are leveraging nimble development programs and targeted indications to enter niches where unmet needs persist, often pursuing partnerships with larger organizations to scale commercialization and distribution. Concurrently, contract manufacturers and generic entrants are influencing pricing dynamics, especially when patent cliffs or exclusivity expirations create opportunities for lower-cost alternatives. Across the competitive landscape, strategic collaborations-for example, co-promotion, distribution agreements, and evidence-sharing compacts-are increasingly common as companies seek to align capabilities and mitigate market access risk.

Manufacturers are also prioritizing operational excellence in manufacturing robustness, serialization, and supply chain transparency to meet regulatory and payer expectations. Developing compelling value narratives that connect clinical differentiators to patient-centric outcomes, adherence benefits, and health-economic impacts will remain central to winning formulary positions and fostering durable adoption in a crowded oral therapy marketplace.

Actionable strategic priorities for industry leaders to align evidence, supply resilience, patient support, and adaptive contracting in oral multiple sclerosis commercialization

Industry leaders should adopt a multi-dimensional playbook that aligns clinical differentiation, evidence generation, and commercial agility to capture durable value in the oral multiple sclerosis environment. First, prioritize a precision evidence plan that includes head-to-head comparisons where feasible, robust real-world evidence programs, and long-term safety registries that directly address payer concerns and clinician decision-making criteria. This evidence base should be designed to support both national health technology assessments and localized payer dialogues.

Second, invest in supply chain redundancy and manufacturing flexibility to mitigate tariff and geopolitical risks. Options such as dual-sourcing of critical ingredients, selective near-shoring, and strategic buffer inventory at regional hubs can preserve continuity of access and guard against sudden cost shocks. Third, develop differentiated patient support and adherence programs that are integrated with specialty pharmacy partners and that use digital tools to improve persistence and outcomes; these programs are tangible levers for payers when assessing real-world value.

Fourth, deploy adaptive pricing and contracting mechanisms, including outcomes-based agreements where appropriate, to align reimbursement with demonstrated clinical impact and to facilitate entry into constrained payer markets. Finally, foster cross-functional alignment between medical affairs, market access, commercial, and supply teams to ensure that evidence, pricing, and distribution strategies are cohesive and rapidly executable. Taken together, these actions will enable industry leaders to navigate complexity while accelerating patient access and sustaining competitive advantage.

A rigorous mixed-methods research framework blending clinical literature review, stakeholder interviews, and triangulated evidence to validate oral multiple sclerosis insights

The research methodology underpinning this analysis blends primary and secondary research approaches with rigorous triangulation to ensure analytical robustness and practical relevance. Secondary research included comprehensive review of peer-reviewed clinical literature, regulatory filings, prescribing guidelines, and public policy announcements to establish the clinical and regulatory context for oral multiple sclerosis therapies. This foundation was complemented by synthesis of treatment pathway literature and healthcare delivery reports to map distribution and access channels.

Primary research consisted of structured interviews and targeted consultations with a cross-section of stakeholders, including neurologists with MS expertise, formulary decision-makers, hospital pharmacists, specialty pharmacy leads, and payer representatives. These engagements provided qualitative insights into prescribing rationales, reimbursement drivers, and operational constraints that shape real-world adoption. Data from these primary sources were cross-checked against secondary evidence and anonymized aggregated claims where permissible to validate patterns and identify divergences between trial-based expectations and clinical practice.

Analytical processes emphasized triangulation across data streams, sensitivity checks for tariff and supply chain scenarios, and segmentation validation informed by molecule, class, indication, line of therapy, dosage form, and distribution channel lenses. Limitations are acknowledged where data gaps exist, particularly in rapidly evolving regulatory domains or nascent real-world evidence for newer agents. Wherever possible, uncertainty was reduced through iterative expert review and scenario analysis to present a balanced and actionable account for decision-makers.

High-level synthesis linking clinical differentiation, operational resilience, and tailored market access to actionable conclusions for oral multiple sclerosis stakeholders

In summary, the oral multiple sclerosis landscape presents both heightened complexity and clear avenues for strategic advantage. Molecular diversity across agents such as fumarates, sphingosine receptor modulators, and dihydroorotate dehydrogenase inhibitors has enriched therapeutic choice but increased the demand for comparative evidence and differentiated value communication. Tariff and supply chain considerations in 2025 add an operational dimension that compels manufacturers to integrate cost, resilience, and access strategies more tightly than before.

Regional variations in regulatory rigor, payer structures, and distribution architectures mean that global strategies must be adapted for local execution, with focused investments in evidence packages that meet specific jurisdictional requirements. Company strategies that combine robust clinical evidence, agile manufacturing and supply, patient-centered support, and creative contracting will be best positioned to secure formulary placement and clinician preference. The overarching conclusion is that success in this category will rely less on a single promotional lever and more on the ability to synchronize clinical, operational, and commercial functions around demonstrable patient and payer value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oral Medications for Multiple Sclerosis Market, by Molecule

  • 8.1. Dimethyl Fumarate
  • 8.2. Diroximel Fumarate
  • 8.3. Fingolimod
  • 8.4. Monomethyl Fumarate
  • 8.5. Ozanimod
  • 8.6. Ponesimod
  • 8.7. Siponimod
  • 8.8. Teriflunomide

9. Oral Medications for Multiple Sclerosis Market, by Drug Class

  • 9.1. Dihydroorotate Dehydrogenase Inhibitors
  • 9.2. Fumarates
    • 9.2.1. Dimethyl Fumarate
    • 9.2.2. Diroximel Fumarate
    • 9.2.3. Monomethyl Fumarate
  • 9.3. Sphingosine 1 Phosphate Receptor Modulators
    • 9.3.1. Fingolimod
    • 9.3.2. Ozanimod
    • 9.3.3. Ponesimod
    • 9.3.4. Siponimod

10. Oral Medications for Multiple Sclerosis Market, by Indication

  • 10.1. Clinically Isolated Syndrome
  • 10.2. Relapsing Remitting Multiple Sclerosis
  • 10.3. Secondary Progressive Multiple Sclerosis Active

11. Oral Medications for Multiple Sclerosis Market, by Line Of Therapy

  • 11.1. First Line
  • 11.2. Later Line
  • 11.3. Second Line

12. Oral Medications for Multiple Sclerosis Market, by Dosage Form

  • 12.1. Capsule
  • 12.2. Tablet

13. Oral Medications for Multiple Sclerosis Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Retail Pharmacy
  • 13.3. Specialty Pharmacy

14. Oral Medications for Multiple Sclerosis Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Oral Medications for Multiple Sclerosis Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Oral Medications for Multiple Sclerosis Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Oral Medications for Multiple Sclerosis Market

18. China Oral Medications for Multiple Sclerosis Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Acorda Therapeutics, Inc.
  • 19.7. Bayer AG
  • 19.8. Biogen Inc.
  • 19.9. Bristol-Myers Squibb Company
  • 19.10. Clene Nanomedicine, Inc.
  • 19.11. Eisai Co., Ltd.
  • 19.12. F. Hoffmann-La Roche Ltd.
  • 19.13. GlaxoSmithKline plc
  • 19.14. Immensa Biotherapeutics, Inc.
  • 19.15. Immunic, Inc.
  • 19.16. Janssen Pharmaceuticals, Inc.
  • 19.17. Merck KGaA
  • 19.18. Mitsubishi Tanabe Pharma Corporation
  • 19.19. Novartis AG
  • 19.20. Oryzon Genomics, S.A.
  • 19.21. Pfizer Inc.
  • 19.22. Sanofi
  • 19.23. Teva Pharmaceutical Industries Ltd.
  • 19.24. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIMETHYL FUMARATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIMETHYL FUMARATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIMETHYL FUMARATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIROXIMEL FUMARATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIROXIMEL FUMARATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIROXIMEL FUMARATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FINGOLIMOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FINGOLIMOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FINGOLIMOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MONOMETHYL FUMARATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MONOMETHYL FUMARATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MONOMETHYL FUMARATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY OZANIMOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY OZANIMOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY OZANIMOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY PONESIMOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY PONESIMOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY PONESIMOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SIPONIMOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SIPONIMOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SIPONIMOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY TERIFLUNOMIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY TERIFLUNOMIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY TERIFLUNOMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIMETHYL FUMARATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIMETHYL FUMARATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIMETHYL FUMARATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIROXIMEL FUMARATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIROXIMEL FUMARATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIROXIMEL FUMARATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MONOMETHYL FUMARATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MONOMETHYL FUMARATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MONOMETHYL FUMARATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FINGOLIMOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FINGOLIMOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FINGOLIMOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY OZANIMOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY OZANIMOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY OZANIMOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY PONESIMOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY PONESIMOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY PONESIMOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SIPONIMOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SIPONIMOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SIPONIMOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY CLINICALLY ISOLATED SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY CLINICALLY ISOLATED SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY CLINICALLY ISOLATED SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY RELAPSING REMITTING MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY RELAPSING REMITTING MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY RELAPSING REMITTING MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS ACTIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS ACTIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS ACTIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LATER LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LATER LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LATER LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. GCC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GCC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 182. GCC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 183. GCC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 184. GCC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 185. GCC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. GCC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. GCC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 188. GCC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. G7 ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. G7 ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 209. G7 ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 210. G7 ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 211. G7 ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 212. G7 ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 213. G7 ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. G7 ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 215. G7 ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. NATO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. NATO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 218. NATO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 219. NATO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 220. NATO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 221. NATO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 222. NATO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. NATO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 224. NATO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)